Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 08, 2021
Showing 1-1 of 1
Last Updated: 09/26/2026